MedTrace Logo

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

NCT01101295 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2012-03-21

No results posted yet for this study

Summary

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.

Conditions

  • Purpura, Thrombocytopenic, Idiopathic
  • Autoimmune Thrombocytopenia

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Henri Mondor University Hospital

    lead OTHER

Principal Investigators

  • Bertrand GODEAU, MD · National Reference Center for Study of Cytopenia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-04-30
Completion
2017-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101295 on ClinicalTrials.gov